A phase I/II study of the PARP inhibitor, ABT-888 plus 5-fluorouracil and oxaliplatin (modified FOLFOX-6) in patients with metastatic pancreatic cancer.

Michael J. Pishvaian, Jonathan R. Brody, Agnes Witkiewicz et al.|Journal of Clinical Oncology|2011

Cited by 6